Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213
Public ClinicalTrials.gov record NCT05305989. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Extended Treatment and Follow-up of Subjects Treated with Belumosudil in Study KD025-208 or Study KD025-213
Study identification
- NCT ID
- NCT05305989
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 23 participants
Conditions and interventions
Conditions
Interventions
- Belumosudil 200 mg QD Drug
- Belumosudil 200 mg BID Drug
- Belumosudil 400 mg QD Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 23, 2022 (Actual)
- Primary completion
- Jun 6, 2024 (Actual)
- Completion
- Jun 6, 2024 (Actual)
- Last update posted
- May 2, 2025
2022 – 2024
United States locations
- U.S. sites
- 8
- U.S. states
- 5
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope Site Number : 050 | Duarte | California | 91010 | — |
| Stanford Cancer Center Site Number : 108 | Stanford | California | 94305 | — |
| Washington University School of Medicine Site Number : 125 | St Louis | Missouri | 63110 | — |
| University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center Site Number : 132 | Pittsburgh | Pennsylvania | 15232 | — |
| South Austin Medical Center Site Number : 091 | Austin | Texas | 78704 | — |
| MD Anderson Cancer Center Site Number : 057 | Houston | Texas | 77030-4009 | — |
| Texas Transplant Institute Site Number : 079 | San Antonio | Texas | 78229 | — |
| Fred Hutchinson Cancer Research Center Site Number : 052 | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05305989, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 2, 2025 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05305989 live on ClinicalTrials.gov.